ArticleRheumatology and therapy2022

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

Roy M Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.